viewSynairgen PLC

Synairgen phase II study making encouraging progress

The company is trialling an inhaled interferon beta treatment in lung disease patients who are also suffering from either a cold or flu

researcher filling a vial
In all 15 centres are up and running for the trial, which will take in the 2019/20 “virus season”

Synairgen plc (LON:SNG) appears to be making encouraging early progress with its inhaled interferon beta treatment, which is currently undergoing a phase II clinical trial.

The study will assess the drug’s potential to treat people with a progressive lung disease called COPD that also have confirmed common cold and influenza virus infections.

These exacerbations, as they are called, pose significant health risks, particularly in the winter virus season.

Chief executive Richard Marsden said the company is “successfully capturing marked changes” in patients with COPD that also have the aforementioned viruses.

15 centres up and running 

In all 15 centres are up and running for the trial, which will take in the 2019/20 “virus season” with participants screened specifically to assess whether they have cold or flu.

The test ensures that only people for whom the IFN-beta therapy may be effective are dosed, thereby increasing the chance of success.

"Aided by the rapid point-of-care test, the trial is successfully capturing marked changes in COPD symptoms in patients with confirmed common cold and influenza virus infections,” said CEO Marsden.

“We have previously shown that inhaled IFN-beta boosts the lungs' antiviral defences in COPD patients and the magnitude of the symptom changes being observed so far in the current trial puts us in a good position to determine the potential benefit of inhaled IFN-beta in this patient population."

The shares rose 6.3% to 11p.

---Adds share price---

Quick facts: Synairgen PLC

Price: 50 GBX

Market: AIM
Market Cap: £74.72 m


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Synairgen PLC named herein, including the promotion by the Company of Synairgen PLC in any Content on the Site, the Company receives from said...



Synairgen CEO details expansion of key coronavirus trial to patients in home

Synairgen PLC's (LON:SNG) CEO Richard Marsden caught up with Proactive London's Andrew Scott after announcing that the trial of its SNG001 interferon-beta treatment will be extended to coronavirus patients in the home environment. He says the idea behind the move is to dose patients with the...

11 hours, 1 minute ago

2 min read